From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year ...

Melissa Leichter, a Novo Nordisk executive, describes the distinct skills and mindset needed to succeed in bringing rare disease treatments to market.

Then: In a 2021 “Companies To Watch” article written by Wayne Koberstein, Carisma Therapeutics CEO Steven Kelly spoke about his three-pronged mandate to fund the (then) privately held company, build a ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

We live in an era of extraordinary scientific advancement, and as a result, we are seeing rapid growth in the development of new drugs. When the clinical trial ecosystem works, we deliver on our ...

While the needle remains the most common delivery vehicle for vaccines, a large number of patients suffer from needle phobia, making the intranasal delivery route a promising alternative to help boost ...

Life Science Leader is an essential business publication for life science executives who work at everything from emerging biotechs to large pharmaceutical companies. Our content is designed to inform ...

Over the past decade, advances in drug discovery and clinical development have led to a rise in the number of approved therapies, resulting in an increasingly competitive marketplace. These evolving ...

Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market ...